<DOC>
	<DOCNO>NCT00532168</DOCNO>
	<brief_summary>There randomize clinical trial advance HIV patient . This multicenter , randomize , open clinical trial , compare three parallel group , compare immunological reconstitution virological efficacy safety three different combination antiretroviral therapy give day ( QD ) : tenofovir plus emtricitabine plus either efavirenz , lopinavir-ritonavir atazanavir-ritonavir 96 week advance antiretroviral na√Øve HIV-1 infect patient less 100 CD4+ T-cells/mm3 . Primary endpoint median increase CD4+ T-cell count 48 week start HAART .</brief_summary>
	<brief_title>Once-daily Antiretroviral Therapy HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Chronic HIV1 infection Age 18 Antiretroviralnaive Baseline CD4+ count &lt; 100 cels/mcL . No mutation drug resistance baseline ( M184V/I , K65R , resistance efavirenz 2 PRAMs ( L33I/F/V , V82A/F/L/T , I84V , L90M ) Written informed consent Hypersensibility study drug . Pregnancy breastfeed Active OI require admission Active lymphoma malignancy ( Kaposi sarcoma include ) Cl creatinine 30 ml/min . Liver failure Treatment nephrotoxic drug , immunomodulators , interleukine2 , systemic steroid investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>advanced HIV-infected patient</keyword>
	<keyword>late presenter</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>immune reconstitution</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>